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ABSTRACT
Alzheimer’s disease (AD) is a neurodegenerative condition that affects 1 in 9
people over the age of 65, an estimated 5.4 million Americans. It is the only disease
among the top 10 that cannot be prevented, cured, or treated. Based on the lack of a
viable therapeutic for the prevention or cure of AD, it is vital that therapeutic research for
AD continues. AD is characterized by the deposition of extracellular neuritic plaques
comprised of insoluble amyloid-β (Aβ) fibrils. These plaques are formed from the
amyloidogenic aggregation of Aβ monomer, generated from the cleavage of the amyloid
precursor protein (APP) by β-secretase (BACE1) and γ-secretase. Aβ monomer aggregates
via a nucleation-dependent pathway to form insoluble Aβ fibrils (fAβ). Many Aβ
aggregates formed along the nucleation-dependent pathway are neurotoxins, associated
with cognitive decline and neuronal loss observed in AD patients. Thus, one therapeutic
strategy is to target the production of A and/or its subsequent aggregation.
Epidemiological studies have associated green tea, rich in catechin polyphenols,
and black tea, rich in theaflavin polyphenols, with reduced incidence of AD. The present
study sought to explain this correlation, by identifying their potential to act as multi-target
therapeutic drugs for AD by 1) altering the mechanistic aggregation of Aβ and 2) altering
Aβ1-42 oligomer-induced expression of key AD-associated mRNAs.
Catechins and theaflavins showed mechanistic inhibition towards Aβ aggregation.
Catechins inhibit only the late stages of Aβ soluble aggregate growth, suggesting the
iv

ability to bind only large Aβ aggregate conformations. Theaflavins displayed a
more sweeping capability, showing slight to prominent inhibition across the mechanistic
steps of Aβ aggregation. Both catechins and theaflavins were able to alter the morphology
of fAβ made in their presence. fAβ structural conformation, or morphology, has been
correlated with cytotoxic effects.
While theaflavins showed promising capabilities to inhibit the overall mechanistic
aggregation of Aβ, catechins displayed higher capabilities to alter Aβ-oligomer induced
expression of key AD-associated mRNAs. Epigallocatechin (EGC) and epigallocatechin
gallate (EGCG) through antioxidant and antiaggregation capabilities, respectively, were
able to attenuate the oligomer induced upregulation of APP, thus potentially reducing the
APP protein that can be cleaved to release A. Additionally, through antiaggregation
capabilities EGC and EGCG were able to significantly increase RNA expression of ADAM10,
which cleaves APP in a manner that prevents A release. All catechins were able to
attenuate Aβ-induced expression of BACE1 mRNA through antiaggregation capabilities.
In combination, these studies identify the capabilities of catechins to alter the preprocessing and post-processing of Aβ, supporting their potential to act as multi-target
therapeutics.
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CHAPTER 1: BACKGROUND AND SIGNIFICANCE
1.1 Alzheimer’s Disease Pathogenesis
Alzheimer’s disease (AD) is a neurodegenerative condition that affects 1 in 9 people
over the age of 65, an estimated 5.4 million Americans.1 Individuals with AD exhibit a
decline in cognitive functions: memory, speech, judgment, planning, etc., which in turn
affects their everyday activities ultimately resulting in their need for a caregiver. AD is the
most common form of dementia and the 6th leading cause of death in the United States.
It is the only disease among the top 10 that cannot be prevented, cured, or treated.1 While
other top leading causes of death, such as heart disease, cancer, and stroke, have
decreased between the years 2000 and 2013, the number of AD fatalities has increased
by 71%. It is estimated that in 2050 13.8 million Americans will be affected with AD. 1 The
current FDA approved drugs for AD, such as Aricept, Razadyne, Namenda, and Exelon,
cannot stop the disease but can only aid the treatment of the symptoms.2 Based on the
lack of viable therapeutics for the prevention or cure of AD and the drastically increasing
number of AD cases, it is vital that therapeutic research for AD continues.
Postmortem examinations of AD-ridden brains have shown several reoccurring
abnormal cellular pathologies: loss of synapses, microglial activation, and inflammatory
processes.3 Two additional hallmarks of AD are the deposition of intraneuronal
neurofibrillary tangles composed of hyperphosphorylated tau protein and extracellular
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neuritic plaques comprised of aggregated amyloid-β (Aβ).4,5 In vivo studies have shown
that when amyloid plaques are targeted and sequentially removed, hyperphosphorylated
tau also disperses.6,7 Additionally, mouse models of AD have demonstrated that Aβ
plaques appear before the neurofibrillary tangles, implicating the accumulation of
aggregated Aβ as the primary pathogenesis of AD.6,7 Since derivation of this amyloid
cascade hypothesis in 1991,8 it has been the leading focus of research into therapeutic
treatments of AD.9 This hypothesis states that the naturally occurring soluble Aβ
monomer aggregates via a nucleation-dependent pathway to form insoluble Aβ fibrils
(fAβ). All Aβ aggregates formed along the nucleation-dependent pathway are
inflammatory components and neurotoxins, which in turn causes cognitive decline and
neuronal loss observed in AD patients.10
1.2 Amyloid-β Peptide
Aβ is an amphipathic peptide that originates from the proteolytic processing of the
amyloid precursor protein (APP). APP is a transmembrane glycoprotein that is
concentrated in synapses and neurons; the actual function of the protein is still unknown.
In AD, APP undergoes sequential cleavage by -secretase (BACE1) at the N-terminus and
γ-secretase at the C-terminus to produce Aβ (Figure 1.1).11 Cleavage by γ-secretase occurs
within the transmembrane domain of APP and can produce an Aβ peptide that ranges
from 38-43 amino acids. The two most common forms of Aβ are Aβ1-40 and Aβ1-42. While
Aβ1-42 only encompasses approximately 10% of Aβ present, it has a higher predisposition
to aggregation due to its greater hydrophobicity.12
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Once released from APP, Aβ can aggregate via a nucleation-dependent pathway
(Figure 1.2) in which the Aβ monomer nucleates to form oligomers that then coalesce to
form soluble aggregates. These soluble aggregates are then simultaneously thickened
through association and lengthened through elongation to form insoluble fibrils that
deposit as extracellular neuritic plaques.4,5 Studies have shown Aβ oligomers to be the
most toxic Aβ aggregate,13–15 placing emphasis on inhibiting the mechanistic aggregation
of Aβ at the earlier stages.16 The rate and method in which Aβ aggregates is dependent
upon Aβ’s physiochemical features, such as hydrophobicity, secondary structure, charge,
and aromatic interactions.17 Alterations to these physiochemical features are possible
avenues to modulate Aβ aggregation and toxicity of aggregates formed.18 Each stage of
Aβ aggregation presents a possibility for pharmacological manipulation to interrupt the
aggregation, thus interrupting the pathogenesis of AD.19
1.3 Therapeutic treatment of Alzheimer’s disease by polyphenols
The conundrum of the “French paradox” has led to the premise that nature itself may
have already created useful therapeutic agents. The “French paradox” identified that a
population who consumed moderate amounts of red wine (two to four glasses a day)
even in the presence of a high fat diet had a reduced incidence of coronary artery disease
and AD. Upon further research into the composition of red wine, the beneficial attributes
correlate with the high abundance of natural polyphenols within the beverage. The
“French paradox” has led to many epidemiological studies that have researched the
beneficial attributes associated with the consumption of large quantities of natural
polyphenols in relation to a reduced risk of a multitude of diseases, including AD.4,20,21
3

Polyphenols encompass a large group of natural and synthetic small molecules that
are known for containing one or more aromatic rings and possessing antioxidant
properties.17,22 Figure 1.3 shows the different classifications of over 800 known natural
polyphenols. Polyphenols can be categorized into subgroups based on their structures,
intramolecular interactions, functional groups, and basis of natural or synthetic
production. Naturally produced polyphenols are commonly found in high concentrations
in wine, tea, cocoa, nuts, berries, and a wide variety of other plants. Synthetically
produced polyphenols are commonly used as pH indicators in cell culture media and food
additives.17
In relation to AD, studies have shown that polyphenols bind to Aβ through different
mechanisms. Some polyphenols are sequence specific in their binding, while others are
conformation-dependent, thus possessing different inhibitory capabilities at the different
mechanistic steps of Aβ aggregation.17 In addition to inhibiting Aβ aggregation,
polyphenols have been shown to scavenge free radicals thereby reducing oxidative stress
induced by reactive oxygen species (ROS), stimuli for inflammation.

17,22

Aβ aggregates

are associated with the production of ROS,17,23–26 producing oxidative stress linked with
the age-associated cognitive decline and neuronal loss seen in AD.22 ROS acts as a
messenger that activates downstream signaling pathways, such as the activation of iNOS,
interleukin-1, nuclear factor kappa B (NFκB), and tumor necrosis factor- α (TNF-α).
Stimulation of these genes results in the activation of microglia and astrocytes; and
oxidative stress-mediated neuroinflamation, characteristics associated with AD. 22
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1.4 Flavanols: Catechins and Theaflavins
Green tea, rich in catechin polyphenols, and black tea, rich in theaflavin
polyphenols, have been associated specifically with prevention of obesity, breast cancer,
coronary heart and cardiovascular disease, and reduced risk of AD.21,27,28,29, 30 Catechins
and their derivatives are part of the polyphenol subgroup flavanols, which are
distinguishable from other anthoxanthin sub-groups by the additional hydroxyl at
position 3 (Figure 1.3). Catechins and derivatives are constituents of the Camellia Sinensis
tealeaf and, along with other flavanols and flavonols, comprise 30% of the dry tealeaf’s
weight. These polyphenols can be found in green, black, white, and oolong teas. The
primary flavanols present in tealeaves are catechins. The parent compound of the
catechin family is found in two isomer forms: catechin, the trans isomer, and epicatechin
(EC), the cis isomer. This research focuses on the cis parent isomer, EC, structure and its
derivatives based on their higher abundance in green tea. Epigallocatechin gallate (EGCG)
is the main polyphenolic constituent of green tea leaves. HPLC analysis of green tea leaves
revealed it comprises 60% of the total catechins isolated; that is, 10% of the total
extracted dry tealeaf weight. EGCG represents the most abundant catechin followed by
epigallocatechin (EGC) and then EC.24 The parent compound EC undergoes hydroxylation
to produces EGC; EGC can then be acetylated with gallic acid to form EGCG.
Once tea leaves are harvested, they are either immediately steamed and dried to
preserve the “green,” un-oxidized characteristics of the leaves or allowed to ferment for
a period of time before being heated to stop the enzymatic reaction used to create black
tea leaves. During this enzymatic process, the catechins undergo oxidative coupling to
5

produce oligomeric polyphenolic compounds, theaflavins.31–33 Coupling of EC and EGC
produces theaflavin (TF), while the oxidative coupling of EGC and EGCG produces
theaflavin monogallate (TFG) (Figure 1.4).31
Catechins and derivatives are of great interest because of their natural role in
plants, their association with decreased cognitive impairment, and their known
bioavailability. Research has shown that EC, EGC and EGCG are bioavailable after oral
consumption, and can be found in the plasma.34–40Additionally, EGCG40 and EC36 have
been found to cross the blood brain barrier.22 EC metabolites in glucuronides, methylated
and sulfated forms have been identified to reach and accumulate in the brain at ~400nM
concentrations.37 Research has shown that through continual daily intake the
bioavailability of EC increases.39 The bioavailability of theaflavins is still not understood
and continued research is needed to determine their ability to cross the blood brain
barrier and their produced metabolites. Catechins and their derivatives will be analyzed
for their strongest point of action in the modulation of pre-processing and postprocessing of Aβ, investigating their capabilities to become a multi-target drug.
1.5 Study Overview
This study investigated the hypothesis that green tea catechins and their derivatives
can act as multi-target therapeutics by altering pre-processing and post-processing
pathways in AD. Catechins and their derivatives’ individual capabilities to alter the preprocessing and post-processing of Aβ were examined separately. These studies comprise
the two aims of this work and are described below.

6

1. 4. 1 Green tea catechins and black tea theaflavins mechanistically inhibit Aβ
aggregation in Alzheimer’s disease
The first aim tested the hypothesis that green tea catechins and black tea
theaflavins can inhibit the overall and individual mechanistic steps of Aβ monomer
aggregation. Four assays were used to target unique steps along the aggregation
pathway: a monomer aggregation assay to monitor the overall aggregation process; an
oligomerization assay to monitor the initial nucleation step; an association assay to
monitor the late stage lateral binding of soluble aggregates; and an elongation assay to
monitor the late stage lengthening of soluble aggregates. The objective is to identify
catechins and theaflavins that can prevent or reduce the amount of different Aβ
aggregate species formed. By comparing the inhibitory capabilities of this family of dietary
relevant catechins and their polyphenolic oligomers, theaflavins, the proposed studies
will elucidate key structural elements within these naturally occurring inhibitors of A
aggregation. These structural observations can aid in the development of a better
inhibitor compound.
1. 4. 2 Green tea catechins and black tea theaflavins alter key RNA expression in
Alzheimer’s disease
This chapter tested the hypothesis that green tea catechins and black tea theaflavins
can alter the expression of key RNAs in AD. Research has shown that stressors such as Aβ
can result in increased levels of long non coding RNA (lncRNA) BACE1-antisense transcript
(BACE1-AS) in human SH-SY5Y neuroblastoma cells, a regulator of β-secretase-1
(BACE1).41,42 BACE1-AS regulates BACE1 expression by increasing BACE1 mRNA stability
7

and generating additional BACE1 through a ‘post-transcriptional feed-forward
mechanism’ that results in increased levels of BACE1 and subsequently increased Aβ.42
This aim examined the capabilities of catechins and theaflavins to attenuate this ‘posttranscriptional feed-forward mechanism’ by altering BACE1 mRNA and other key ADassociated mRNAs expression. Real time quantitative polymerase chain reaction (qRTPCR) will be used to analyze alterations in the relative RNA expression of BACE1, ADAM9,
ADAM10, APP, and presenilin 1 (PS1). Alterations in each of these RNA expressions can
have an effect on prognosis of AD.

8

Figure 1.1. Amyloidogenic cleavage of APP.43 APP is sequentially cleaved by β-secretase
(BACE1) and γ–secretase to produce the Aβ peptide. This peptide can follow an
amyloidogenic pathway resulting in Aβ aggregation. These aggregates accumulate
extracellularly with in the brain as neuritic plaques.
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Figure 1.2. Nucleation-dependent pathway of Aβ. Aβ aggregation occurs by the nucleation of Aβ monomer to oligomers, oligomers
then coalesce to form soluble aggregates that grow through simultaneous elongation and association to produce insoluble fibrils.

Figure 1.3. Properties based categorization of polyphenols.22 The different categories
are based upon their structure, intramolecular interactions, functional groups, and origin
(natural or synthetic).
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12
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Figure 1.4. Catechins and Theaflavins. Catechin (EC, EGC, and EGCG) structures vary from hydroxylation to acetylation with a gallic
acid. Theaflavin (TF and TFG) are the product of catechin oxidative coupling, during the tealeaf fermentation process. The theaflavin
structures formed are dependent upon the catechins that were oxidatively coupled to produce the new derivative.

CHAPTER 2: MATERIALS AND METHODS
2. 1

Materials
(-)-Epicatechin, (-)-epigallocatechin, (-)-epigallocatechin gallate, theaflavin, and

theaflavin monogallate were purchased from Sigma-Aldrich (St. Louis, MO) and stored at
-4°C for catechins and at -20°C for theaflavins. Aβ1-40 and Aβ1-42 was purchased from
AnaSpec, Inc. (San Jose, CA) and was stored at -20°C and -80°C respectively. Bovine serum
albumin (BSA), Thioflavin T (ThT), sodium chloride (NaCl), sodium hydroxide (NaOH),
phosphate buffered saline (PBS), and 1, 1, 1, 3, 3, 3-hexafluoro-2-propanol (HFIP) were
purchased from Sigma Aldrich (St. Louis, MO). Dimethyl sulfoxide (DMSO) was purchased
from VWR (Radnor, PA).
2. 2

Aβ1-40 Monomer Purification
Lyophilized Aβ1-40 peptide was purified prior to experimentation. Fast

protein liquid chromatography (FPLC) that utilizes size exclusion chromatography (SEC)
on a Superdex 75 HR 10/300 column (GE Healthcare, Piscataway, NJ, USA) was used to
remove any preformed aggregates and salts. Prior to injection Aβ1-40 was reconstituted in
50 mM NaOH at 2 mg/mL to minimize the formation of small aggregates. Remaining
aggregates were excluded in 40 mM Tris-HCl (pH 8.0) via the purification process. To aid
in the reduction of nonspecific Aβ interaction with the dextran matrix of the column, the
system was pretreated with bovine serum albumin (BSA, 2 mg/mL). Based on the UV
(mAU) elution curve (Figure 2.1, red curve) the fractions of pure monomer were collected
13

for future experiments and additional large preformed aggregates were eluted in the void
volume (9-11 mL). Concentrations of the collected fractions were determined using UV
and the extinction coefficient of 1450 M-1cm-1 at 280 nm.44,45 SEC-purified Aβ1-40
monomer fractions were used fresh or stored at -4°C, up to 4 days. This Aβ1-40 monomer
was used for monomer aggregation, fAβ preparation, production of soluble aggregates,
and elongation assays.
2. 3

Soluble Aβ1-40 Aggregate Preparation and Purification

Aβ1-40 soluble aggregates are intermediates between oligomers and fibrils. They were
produced via the agitation (500 rpms) of 90-100 μM Aβ1-40 monomer combined with 50
mM NaCl in 40 mM Tris-HCl (pH 8.0). The sample was monitored for aggregation via
thioflavin T (ThT) fluorescence. ThT is a benzathiole dye that binds to the β-sheet structure
of Aβ aggregates, but not monomer or unordered species.46 When bound, ThT undergoes
a structural change and a shift in its Ex/Em to 450/485 nm. The fluorescence of the sample
was monitored by combining 140 μL of 10 µM ThT and 10 μL of sample. After the
fluorescence surpasses a value of extensive aggregate formation, a 30 μL aliquot of the
agitated sample was centrifuged at 14,000 rpm for 5 min; the fluorescence of the
supernatant was taken. A significant decrease in the fluorescent reading of the
supernatant, relative to the unspun sample, is indicative of Aβ fibril formation. Aβ1-40
soluble aggregate aggregation was halted before extensive fAβ formation. The
hydrodynamic radius (RH) of the sample was also monitored using dynamic light scattering
(DLS), to ensure the reaction was within soluble aggregates size range (60-100 nm). The
sample was purified using FPLC on a SEC Superdex 75 HR 10/300 column in 40 mM Tris14

HCl (pH 8.0) elution buffer. To aid in the reduction of nonspecific Aβ interaction with the
dextran matrix of the column, the system was treated with BSA, 2 mg/mL, prior to Aβ1-40
injection. Figure 2.1 displays a typical soluble aggregate elution curve (black curve), where
soluble aggregates were collected within the void volume and residual monomer was
eluted with salt between 15-20 mL. Aβ1-40 soluble aggregate concentration within the
collected fractions as determined by UV and a calculated extinction coefficient of 1450M1 cm-1 corrected for light scattering. In addition, ThT fluorescence of isolated Aβ
1-40 soluble

aggregates was measured. Soluble Aβ1-40 aggregates were used in association and
elongation assays. Soluble aggregates were stored up to 3 days and by using ThT
concentration were re-evaluated before every experiment.
2. 4

Preparation of fAβ

Aβ1-40 monomer described from Section 2.2 was combined with NaCl for a final
concentration of 60 µM Aβ1-40, 250 mM NaCl in 40mM Tris-HCl (pH 8.0). The mixture was
vortexed at 800 rpm for 48 h (25°C) before centrifugation at 15,000 rpm for 15 min, the
supernatant was removed and the fibril pellet was resuspended. ThT fluorescence
readings, as described in Section 2.3 were taken before centrifugation and after
resuspension and used to determine concentration of fAβ. The concentration was
calculated by assuming the residual monomer was negligible, and multiplying the fraction
of resuspended ThT fluorescence over pre-centrifugation ThT fluorescence by the initial
monomer concentration.
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2. 5

Preparation of Catechins and Theaflavins

Catechins and theaflavins were respectively stored at -4°C and -20°C. Prior to each use
catechins and theaflavins were prepared fresh by dissolving in filtered diH2O.
2. 6

Preparation of Aβ1-42 Oligomers

Aβ1-42 was reconstituted in cold HFIP to 4mg/mL and incubated on ice (60 min),
aliquoted and HFIP was allowed to evaporate overnight (25°C). The resulting Aβ1-42 films
were stored at -80°C until use. Aβ1-42 oligomers were formed by reconstituting the Aβ1-42
film to 1.5 mM in DMSO with 10-fold molar excess polyphenol or equivalent volume of
filtered diH2O (control). Oligomerization was initiated by the addition of 12 mM
phosphate buffer (PBS, pH 7.4) containing 1 µM NaCl to produce finial concentrations of
15 µM Aβ1-42, 150 μM polyphenol, 1% DMSO, and 1 mM NaCl in PBS. The reaction was
incubated for 30 min (25°C). Oligomers were then either immediately used for 8-anilino1-naphthalenesulphonic acid (ANS) assay, diluted for cell treatment, or the
oligomerization process was halted by the addition of Tween-20 (final concentration
0.1%).
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Figure 2.1. FPLC-SEC purification profile for Aβ1-40 monomer (red) and Aβ1-40 soluble
aggregates (black). The FPLC utilizing SEC elutes large aggregates within the void volume
followed by smaller monomer species of Aβ1-40 within the included volume.
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CHAPTER 3: GREEN TEA CATECHINS AND BLACK TEA THEAFLAVINS MECHANISTICALLY
INHIBIT AΒ AGGREGATION IN ALZHEIMER’S DISEASE
3. 1

Introduction
Epidemiological studies support the abilities of green tea catechins and black tea

theaflavins to attenuate AD. Further research is required to interpret the mechanism by
which these polyphenols interfere in the disease process.21 Previous studies have
suggested that the inhibitory capabilities of some polyphenols are intrinsically altered
dependent upon the mechanistic step at which they intervene, exhibiting conformationdependent binding versus sequence specific binding. 4,5,47,17 To analyze the potential of
catechins and theaflavins to interfere with the amyloidogenic pathway of Aβ, it is crucial
to first understand Aβ’s secondary structure and intermolecular interactions to gain
insight into potential mechanistic inhibition by polyphenols.
While fAβ are noncrystalline solid material and thus cannot been resolved via xray crystallography, several structures of Aβ have been predicted by different techniques,
including x-ray diffraction, nuclear magnetic resonance (NMR) spectroscopy, and
computer simulation.18,48,49 A widely used structural model of fAβ, proposed by Petkova
et al. has given insight into the organization and intermolecular interactions of Aβ (Figure
3.1a). Residues 1-8 are structurally disordered, while residues 12-24 and 30-40 adopt
β-strand conformations and form parallel β-sheets by hydrogen bonding.48 In the
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amyloidogenic pathway, the initial random coil organization of Aβ monomer converts to
a β-sheet secondary structure, a cross-β-sheet pattern, in which a single cross-β unit is a
double layered β-sheet structure with a hydrophobic core and a hydrophobic face. The
only charged sidechains within the core of Aβ are those of D23 and K28, these charged
sidechains form a salt bridge to stabilize the β-sheet structure. The proposed binding of
Aβ is through hydrogen bonding, forming fibrils that contain two cross-β units with their
hydrophobic faces juxtaposed (Figure 3.1b). This model gives essential information
towards the design of inhibitors of the amyloidogenic pathway of Aβ.
Petkova et al.’s proposed model pinpoints several potential physicochemical
features that would aid in the selection of a potential AD therapeutic. For example,
compounds that interact with Aβ’s hydrophobic core could potentially disrupt monomermonomer interaction, destabilizing the nucleation of Aβ oligomers. A sequence specific
binding of Aβ that recognizes residues 12-24, involved in the interaction between fAβ
aggregates, would interfere with lateral association (Figure 3.1c). Alternatively, soluble
aggregate elongation can potentially be inhibited by compound forming hydrogen bonds
with amino or carboxyl groups of residues 12-24 or 30-40.
Catechins and theaflavins exhibit potential physicochemical features that are
suggested to aid in the inhibition of the amyloidogenic aggregation of Aβ. It was
hypothesized that the aromatic rings of catechins and theaflavin would enable them to
interact with the π-π stacking of the phenylalanine residues at 19 and 20. Additionally,
the abundance of hydroxyl groups in catechins and theaflavins (Figure 1.4) suggest a
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higher potential to interact with hydrogen bonding of the amino and carboxyl groups of
residues 12-24 and 30-40, potentially inhibiting elongation of soluble aggregates.
The approach of this aim differs from traditional investigation of potential
therapeutics, by investigating the inhibitory capabilities of catechins, EC, EGC, and EGCG
and theaflavins, TF and TFG, at the different mechanistic steps of Aβ aggregation. Aβ
aggregation was investigated at three specific steps along the amyloidogenic pathway
(Figure 1.2): oligomerization, the rate limiting step of Aβ monomer oligomerization,
elongation, Aβ soluble aggregates are lengthened via the monomeric addition of Aβ to Nor C-terminus, and association, Aβ soluble aggregate growth via lateral interaction.
Typical research focuses on overall Aβ aggregation and early oligomerization. It was
hypothesized that catechins and theaflavins will have unique inhibitory capabilities at the
different mechanistic steps of Aβ aggregation, effecting the overall Aβ aggregation
process. By analyzing the inhibitory capabilities of catechins and theaflavins at the
different mechanistic steps, information was obtained on the importance of key
structural elements. Knowing what structures are key to inhibit the varying mechanistic
steps of Aβ aggregation can aid in producing therapeutic drugs that are capable of
targeting every mechanistic step of Aβ aggregation, inhibiting the pathogenesis of AD.
3. 2

Materials and Methods

3. 2. 1 Materials
Laemmli buffer, 4-20% tris-glycine gels, Precision Plus Protein WesternC standard,
Precision Protein Strep Tactin-HRP conjugate, and 0.2 μm nitrocellulose membranes were
purchased from Bio-Rad (Hercules, CA). Monoclonal antibody 6E10 was obtained from
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Covance (Princeton, NJ). HRP-conjugated anti-mouse secondary antibody, Tween-20 and
chemiluminescent reagents were purchased from VWR (Radnor, PA). 8-anilino-1naphthalenesulphonic acid (ANS) was obtained from Research Organics (Cleveland, OH).
300-mesh formvar-supported copper grids and uranyl acetate were purchased from
Electron Microscopy Science (Hatfield, PA).
3. 2. 2 Assessment of Aβ1-42 Oligomer Size via SDS-PAGE and Western Blot Analysis
To determine if the presence of catechins or theaflavins alters the oligomer size
distribution, Tween-20 (final concentration 0.1%) stabilized Aβ1-42 oligomer products
made in the absence (control) or presence of the polyphenols described in Section 2.6
were mixed 1:1 with Laemmli buffer for size characterization using SDS-PAGE and
Western blot. A1-42 oligomer samples and Precision Plus Protein WesternC standard
were loaded onto a 4-20% Tris-glycine gel and electrophoresed (120V) using a MiniPROTEAN Tetra Cell (Bio-Rad). Protein was electrotransferred (14 V, 12 min) onto a 0.2
µm nitrocellulose membrane via semi-dry transfer cell (Bio-Rad) and blocked (overnight,
4°C) using 5% dry nonfat milk in phosphate buffered saline containing 0.002% Tween
(PBS-T). The membrane was probed (1h) with 6E10 monoclonal antibody (1:2000), a
sequence-specific antibody that binds to the N-terminal region of Aβ. The membrane was
then washed (5 min) three times with PBS-T before incubating (45 min) with HRPconjugated anti-mouse secondary antibody (1:200) and Precision Protein Strep TactinHRP conjugate (1:200). After incubation with the secondary, the membrane was washed
(5 min) three times before being placed in enhanced chemiluminescence regents for 2
min. Images were obtained using the Gel DocTM XRS+ imaging system (Bio-Rad), and
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Image Lab software (Bio-Rad) was used for volumetric analysis of oligomer species within
the 25-100 kDa and 100-250 kDa size ranges. Results are presented as fraction of control.
3. 2. 3 Evaluation of Aβ1-42 Oligomer Conformation via ANS Spectroscopy
ANS spectroscopy was used to evaluate the influence of catechins and theaflavins
on oligomer conformation. ANS is a small molecular dye that undergoes a blue shift and
an increase in fluorescence when bound to exposed hydrophobic residues of a protein or
peptide. This dye has been extensively used in protein folding analysis to identify the
presence of exposed hydrophobic residues and is commonly used as an indicator of Aβ
aggregate conformation, specifically oligomer conformation.49,50,51 ANS was solubilized
in DMSO at 50 mM and stored at 4°C. ANS was further diluted in 12 mM phosphate buffer
(7.4) and added to oligomers made in the absence (control) or presence of catechins or
theaflavins as described in Section 2.6, to a final concentration of 1 µM Aβ1-42, 10 µM
polyphenol, and 100 µM ANS. Fluorescence emission from 400 to 600 nm with excitation
at 350 nm was measured using an LS-45 luminescence spectrophotometer (Perkin Elmer,
Waltham, MA). ANS fluorescence values were determined as the integrated area under
the curve (IAUC) from 450-550 nm with blank (polyphenol with ANS) subtraction. Results
are presented as fraction of control.
3. 2. 4 Determination of the Rate of Aβ1-4o Elongation
An elongation assay was utilized to evaluate the capabilities of catechins and
theaflavins to alter the rate of Aβ1-40 soluble aggregate lengthening via monomer
addition, or elongation.45,52,53 SEC-purified soluble aggregates described in Section 2.4
were diluted in 40 mM Tris-HCl (pH 8.0) and incubated (15 min) alone (positive control)
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or in the presence of 25-fold molar excess of catechins or theaflavins. Elongation was
initiated by the addition of Aβ1-40 monomer (Section 2.2) for final concentrations of 2 μM
Aβ1-40 soluble aggregates, 50 μM polyphenol, and 30 μM Aβ1-40 monomer. Aβ1-40 soluble
aggregates incubated in the absence of Aβ1-40 monomer, NaCl, and polyphenols served as
a negative control and reflected the stability of the soluble aggregates. Aβ1-40 monomer
incubated in the absence of Aβ1-40 soluble aggregates, NaCl, and polyphenols served as a
negative control and reflected the stability of the monomer. Once initiated, the
elongation reaction was placed in a quartz cuvette (path length 1 cm) for continual
monitoring of RH via DLS by a Dyna Pro Temperature-Controlled Microsampler and
DynaPro Titan power source (Wyatt Technology Corporation, Santa Barbra, CA).
Elongation rates were determined by linear regression of temporal increase in RH. Results
were normalized to the positive control.
3. 2. 5 Determination of the Rate of Aβ1-4o Association
An association assay was used to evaluate the capabilities of catechins and
theaflavins to attenuate the rate of lateral binding of Aβ1-40 soluble aggregates, or
association. 45,52,53 SEC-purified soluble aggregates described in Section 2.4 were diluted
in 40 mM Tris-HCl (pH 8.0) and incubated (15 min) alone (positive control) or in the
presence of 25-fold molar excess of catechins or theaflavins. Association was initiated by
the addition of physiological NaCl concentration for final concentrations of 2 μM Aβ1-40
soluble aggregates, 50 μM polyphenol, and 150 mM NaCl. Once initiated, the association
reaction was placed into a quartz cuvette (path length 1 cm) for continual monitoring of
RH via DLS of Dyna Pro Temperature-Controlled Microsampler and DynaPro Titan power
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source (Wyatt Technology Corporation, Santa Barbra, CA). Aβ1-40 soluble aggregates
incubated in the absence of NaCl and polyphenols served as a negative control and
reflected the stability of the soluble aggregates. Association rates were determined by
linear regression of temporal increase in RH. Results were normalized to the positive
control.
3. 2. 6 Evaluation of Aβ1-40 Monomer Aggregation
SEC-purified Aβ1-40 monomer (Section 2.2) was diluted to a final concentration of
20 μM Aβ1-40 monomer, 100 µM polyphenol or equivalent solvent volume (control), and
150 mM NaCl in 40 mM Tris-HCl (pH 8.0). Samples were continuously vortexed at 500 rpm
until Aβ1-40 aggregates plateaued. At pre-determined time intervals, a 30 µL aliquot of the
samples was removed and the extent of aggregation was evaluated using one of three Aβ
aggregate detection methods: ThT fluorescence, dot blot analysis utilizing structure
specific (larger Aβ aggregates) antibody LOC detection, and DLS intensity.
Aβ1-40 monomer aggregation exhibited the characteristic lag period, growth
phase, and plateau. From these graphs, the plateau portion of the experiment was
determined and the average of the plateau was used to normalize all data points (each to
their corresponding graphs). Inhibition was evaluated by determining the lag extent and
plateau reduction. Lag extent was determined as the time required for a significant
change in the detected Aβ aggregates to occur normalized to the control. Plateau
reduction was determined as fraction of control plateau.
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3. 2. 7 Evaluation of Aβ1-40 Monomer Aggregation by ThT Fluorescence
Aβ1-40 monomer aggregation was monitored via ThT fluorescence by combining
140 µL of 10 µM ThT dye and 10 µL of the sample. Fluorescence emission from 400 to 600
nm with excitation at 450 nm was measured using an LS-45 luminescence
spectrophotometer. Measurements were evaluated by calculating the area under the
curve from 470-500 nm. Results are presented as the change in fluorescence over time.
3. 2. 8 Evaluation of Aβ1-40 Monomer Aggregation by LOC Antibody Detection
Aβ1-40 monomer aggregation was monitored via dot blot analysis using LOC
antibody detection performed by adding 4μL of sample drop-wise onto a 0.1 μm
nitrocellulose membrane. The membrane was dried (9 min) at 25°C before placed into 5%
nonfat milk in PBS-T (overnight, at 4°C). The membrane was probed (1h) with LOC
(1:5000) and then washed (5 min) three time with PBS-T before incubation (45 min) with
HRP-conjugated anti-rabbit secondary antibody (1:200) and Precision Protein Strep
Tactin-HRP conjugate (1:200). After incubation with the secondary the membrane was
washed (5 min) three times before being placed in enhanced chemiluminescence
reagents for 2 min. Images were obtained using the Gel DocTM XRS+ imaging system (BioRad), and Image Lab software (Bio-Rad) was used for volumetric analysis to determine
the intensity of each dot. Results are presented as the change in adjusted volume
(intensity) over time.
3. 2. 9 Evaluation of Aβ1-40 Monomer Aggregation by DLS Intensity
Aβ1-40 monomer aggregation was monitored via DLS intensity. The sample’s DLS
intensity was determined by loading the sample into a quartz cuvette (path length 1 cm)
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for continual monitoring using a Dyna Pro Temperature-Controlled Microsampler and
DynaPro Titan power source (Wyatt Technology Corporation, Santa Barbra, CA). Because
Aβ monomer aggregation results in the production of a wide range of aggregate species,
monitoring its RH is not practical. Instead, the more global parameter of intensity was
monitored. Results are presented as increase in intensity over time.
3. 2. 10 Evaluation of LOC and ThT Binding of Aβ Aggregates
Assessment of catechins’ and theaflavins’ ability to alter ThT and LOC binding
signals was performed to facilitate selection of the most effective technique for
monitoring Aβ1-40 monomer aggregation. For ThT analysis, fAβ1-40 (Section 2.4) were
diluted to the equivalent of loading 15 µL Aβ monomer aggregation assay (1:5 molar ratio
of Aβ: polyphenol) into 140 µL 10 µM ThT, for a final concentration of 1.93 μM fAβ in 40
mM Tris-HCl (pH 8.0), 9.67 μM polyphenol or solvent (control), and 9.03 μM ThT. Sample
fluorescence was analyzed as in Section 3.2.7. For LOC analysis, fAβ1-40 diluted to 10 μM
in 40mM Tris-HCl (pH 8.0) with 100 μM polyphenol or solvent (control) was added dropwise (4μL) onto a 0.1 μm nitrocellulose membrane. The membrane was dried (9 min) at
25°C before being placed into 5% nonfat milk in PBS-T (overnight, at 4°C). The membrane
was probed (1h) with LOC (1:5000) and then washed (5 min) three time with PBS-T before
incubation (45 min) with HRP-conjugated anti-rabbit secondary antibody (1:200) and
Precision Protein Strep Tactin-HRP conjugate (1:200).

After incubation with the

secondary, the membrane was washed (5 min) three times before being placed in
enhanced chemiluminescence reagents for 2 min. LOC binding was analyzed as in Section
3.2.8 all samples were quantified and reported as a fraction of the control.
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3. 2. 11Transmission Electron Microscopy
Transmission electron microscopy (TEM) negative staining technique was
implemented to view the fAβ end product of Aβ1-40 monomer aggregation, described in
Section 3.2.6—Section 3.2.9. Negative staining employs a dye that stains the background,
but not the protein itself. TEM transmits a beam of electrons through a sample; the
electrons are scattered by the stain and only permitted to pass through the sample. This
imaging technique allows for qualitative evaluation of the effect of catechins and
theaflavins on the morphology of the fAβ1-40.
Samples were gridded by placing 20 μL of the end product of Aβ1-40 monomer
aggregation reaction onto a 300-mesh formvar-supported copper grid and incubating
(3 min). The remaining solution was wicked off, and this process was repeated a total of
three times. Grids were negatively stained by incubation (8 min) sample side down on a
20 μL droplet of 2% uranyl acetate before solution was wicked off, and the grids dried
overnight (4°C). Grids were imaged using a TEM-1400 Plus Electron Microscope (JEOL) at
120kV.
3. 2. 12 Statistical Analysis
Prism 5 software (Graphpad Software, La Jolla, CA) was used for all statistical analysis.
A one-way analysis of variance (ANOVA) with Dunnett test was used to compare all
samples to the respective control, and an unpaired t-test was used for comparison
between samples. p<0.05 was considered significant. All values are expressed as the
mean ± SEM.
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3. 3

Results

3. 3. 1 Theaflavins Modulate Aβ Oligomer Size and Structure
To evaluate the ability of catechins and theaflavins to alter oligomerization, Aβ1-42
oligomers were formed in the absence (control) or presence of each polyphenol. The size
distribution of resulting oligomers was assessed using SDS-PAGE and Western blot.
Separation of the oligomer products by 4-20% Tris-glycine gel (Figure 3.3a) revealed that
only theaflavins are able to reduce the formation of oligomers in both the 25-100 kDa and
100-250 kDa (Figure 3.3b) size ranges. The Aβ1-42 oligomer result indicates a clear
distinction in the inhibitory capability of catechins and their phenolic derivatives,
theaflavins. In their monomeric form, the catechins have no effect, but when they are
oxidatively coupled to form phenolic derivatives, theaflavins, they are able to significantly
reduce the amount of larger oligomers formed (100-250 kDa). TFG is the only compound
that is also able to significantly reduce the formation of small (25-100 kDa) oligomers.
Studies have shown a direct correlation between Aβ aggregate structure and
toxicity as well as the potential to undergo further aggregation.17,18 The ability of
catechins and theaflavins to alter the conformation of Aβ1-42 oligomers was determined
via ANS (Figure 3.4). ANS binds to exposed hydrophobic residues of proteins and has been
commonly used to determine Aβ aggregate conformation.51 Oligomers formed in the
presence of catechins do not exhibit significantly altered ANS fluorescence when
compared to native oligomers. Aβ1-42 oligomers made in the presence of TFG, however,
exhibit increased ANS fluorescence, suggesting an altered oligomer conformation.
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3. 3. 2 Catechins and Theaflavins Inhibit Growth of Aβ1-40 Soluble Aggregate Intermediates
Elongation and association are the two late-stage mechanistic steps of Aβ
aggregation, which occur simultaneously to produce insoluble fAβ that deposit as neuritic
plaques. Assays that isolate the growth mechanisms were utilized to evaluate the ability
of catechins and theaflavins to alter the late-stages of Aβ1-40 soluble aggregate growth by
monomeric lengthening, or elongation, and lateral binding, or association.
Elongation growth was initiated by addition of Aβ1-42 monomer resulting in
monomeric growth. Accuracy of elongation was determined by no individual change in
the native monomer and soluble aggregate size. When soluble A1-40 aggregates were
pre-incubated in the presence of catechins and theaflavins prior to initiation of elongation
via addition of monomer, all compounds were significantly able to reduce the rate of
elongation by greater than 60% (Figure 3.5). EGCG was the superior inhibitor, completely
abrogating elongation.
Association growth was initiated by addition of physiological salt resulting in
lateral growth. Accuracy of association was determined by no change of native soluble
aggregates size. When incubation of A1-40 soluble aggregates with catechins and
theaflavins was followed by addition of physiological salt to initiate association, varying
inhibitory capabilities were observed for catechins and theaflavins (Figure 3.5). As
compounds are derived from the parent compound EC, hydroxylation to EGC, and
acetylation of EGC with gallic acid to form EGCG, capacity to attenuate association
increased (p<0.05 EC to EGC, p<0.01 EGC to EGCG and p<0.001 EC to EGCG). Catechins,
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EGC and EGCG, and theaflavins, TF and TFG, are all able to significantly reduce the rate of
association.
For both growth mechanisms, elongation and association, EGCG displays superior
inhibition. EGCG is able to completely abrogate both late-stage mechanistic-aggregation
steps of Aβ.
3. 3. 3 Congruence between Aβ1-40 Monitoring Techniques and Polyphenol Interaction
Aβ aggregation was monitored simultaneously using three different methods of
aggregate detection, ThT, LOC antibody detection, and DLS intensity, to verify the validity
of using these techniques interchangeably. The results of each technique were reported
as a fraction of their control’s plateau for comparison purposes (Figure 3.6a).
When normalized to their control’s plateau, the extent of total aggregation was
analogous between the three Aβ aggregate monitoring techniques. All techniques
exhibited equivalent fractions of plateau at the same three phases of Aβ1-40 monomer
aggregation, lag period, growth phase, and plateau. These results demonstrate that these
three methods of monitoring Aβ aggregation can be used interchangeably.
Polyphenols have exhibited the capability to compete with ThT and LOC for
interaction with Aβ1-40 binding sites. To ensure that the compounds within this study do
not interfere with A aggregate detection, detection of fAβ1-40 by ThT and LOC was
performed in the absence and presence of catechins and theaflavins (Figure 3.6b). ThT
and LOC competition is indicated by lowered detection in the presence of the compound
than in its absence. The presence of EGCG, TF, and TFG resulted in reduced detection of
ThT and LOC. Thus, for these compounds, DLS intensity was utilized to monitor the extent
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of Aβ1-40 monomer aggregation. EC and EGC exhibited no significant reduction of ThT or
LOC, and the monitoring technique of LOC antibody detection was used for further Aβ1-40
monomer aggregation analysis.
3. 3. 4 Theaflavins Reduce the Extent of Aβ1-40 Monomer Aggregation, while both
Catechins and Theaflavins Alter fAβ1-40 Morphology
The capabilities of catechins and theaflavins to reduce the extent of Aβ1-40
monomer aggregation was monitored by LOC antibody detection for EC and EGC (Figure
3.7a) and DLS intensity for EGCG (Figure 3.7b), TF, and TFG (Figure 3.7c). Inhibitory
capabilities of polyphenols were evaluated via two parameters, lag time, the time
required for nucleation to occur and the plateau, the overall amount of Aβ aggregates
formed (Figure 3.6d).
Catechins and theaflavins exhibit a trend for altered time required for nucleation,
but it does not reach significance. EC and EGC shorten the time required for nucleation to
occur. EGCG and TF extend the time required for nucleation to occur by approximately
40%, TFG extends the time required for nucleation by approximately 120%. There is a
statistical increase in lag extension from EC and EGC to EGCG (p<0.05 EC to EGCG and EGC
to EGCG). The plateau value of monomer aggregations performed in the presence of
catechins has no significant difference from the control plateau, thus catechins do not
reduce the amount of aggregates formed. Monomer aggregations performed in the
presence of TF and TFG had significantly reduced plateau values compared to the control,
significantly reducing the overall amount of Aβ aggregates formed in their presence by
58% and 79%, respectively. As shown in Figure 3.6d, an inverse relationship is observed
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between the plateau and lag time for both catechins and theaflavins. The superior
inhibitor of Aβ1-40 monomer aggregation is TFG, capable of extending time required for
nucleation and significantly reducing total amount of Aβ aggregate formation.
To observe the effects of catechins and theaflavins on the morphology of
aggregates formed in their presence, the end products of the Aβ1-40 monomer
aggregation were gridded and negatively stained for TEM analysis (Figure 3.8). Typical
morphology of fAβ1-40, exhibited by the control displays a network of thick long spindlelike structures that spread across the image, having no defined beginning or end. A
defined morphology change is observed for fAβ1-40 made in the presence of each studied
compound. fAβ1-40 formed in the presence of EC and EGC have shortened fAβ, indicating
reduced elongation, and reduced thickness with hydroxylation of the compound,
indicating reduced association. fAβ1-40 formed in the presence of EGCG have been
reduced to very short, singular, fibril strands. fAβ1-40 formed in the presence of TF have
unchanged or slightly increased thickness and the length of fAβ1-40 clusters are short in
comparison to the control. TFG has the most pronounced effect on fAβ1-40 morphology.
fAβ1-40 formed in its presence are very short, thin fibrils that are dispersed across the TEM
grids.
3. 4

Discussion
This aim investigated the capability of green tea catechins and their phenolic

derivatives, theaflavins, to inhibit Aβ aggregation via mechanistic inhibition. Aβ
undergoes aggregation to form insoluble fAβ that deposit as extracellular neuritic
plaques, hallmarks of AD.4,5 Aβ first nucleates to form oligomers that then coalesce into
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soluble aggregates. Soluble aggregates are simultaneously thickened through lateral
association and lengthened through elongation via monomer addition to form insoluble
fibrils. Catechins and theaflavins ability to alter individual mechanistic steps of
oligomerization, soluble aggregate elongation, and soluble aggregate association, as well
as the cumulative Aβ aggregation process and morphology of resulting aggregates were
determined.
Evidence suggests that before Aβ monomer can oligomerize it undergoes
misfolding; the exact mechanism of misfolding and its accompanied conformation change
to oligomers is still not known.40,54 Current research has shown that Aβ oligomers are the
most toxic Aβ speices,13–15 placing emphasis on preventing the misfolding and subsequent
oligomerization of Aβ or pushing it to less toxic larger species. Another proposed method
of altering oligomer toxicity18 and propensity to aggregate is structural modification, or
altering oligomer conformation.17 Theaflavins, but not catechins, are able to modulate
Aβ oligomer formation. TF significantly reduces large (100-250 kDa) oligomers, while TFG
significantly reduces both the larger and smaller (25-100 kDa) oligomer species.
Moreover, TFG is the only compound able to significantly alter oligomer conformation,
evidenced by heightened ANS fluorescence indicative of increased exposed hydrophobic
regions within oligomers formed in its presence. TF also increases ANS fluorescence,
although this increase does not reach significance.
Inhibition of Aβ aggregation as an AD therapeutic approach arose from the
correlation between aggregate accumulation as extracellular neuritic plaques and
neurodegeneration association with AD.6,7 The primary hallmark of AD, extracellular
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neuritic plaques, are composed of insoluble fAβ that deposit as long spindle like structures
that exhibit clusters of lateral association. The morphology of fAβ is a result of the
simultaneous soluble aggregate growth via elongation and association. Inhibition of the
mechanistic steps of soluble aggregate growth has the potential to attenuate the
production of insoluble fAβ. Analysis of catechins’ and theaflavins’ inhibitory effect on
soluble aggregate growth reveals that all compounds significantly attenuate the rate of
Aβ1-40 soluble aggregate elongation. Petkova et al.’s model of Aβ fibril formation indicates
a compound that forms hydrogen bonds with the amino or carboxyl groups of residues
12-24 or 30-40 can potentially inhibit the Aβ soluble aggregate growth via elongation. The
substantial number of hydroxyl groups within catechins and theaflavins possess a high
propensity to form hydrogen bonds, providing a potential explanation for the capability
of all compounds examined to significantly decrease the rate of soluble aggregate
elongation. In contrast, catechins and theaflavins capability to attenuate Aβ1-40 soluble
aggregate growth via association follows a structural trend. Hydroxylation of EC to EGC
statistically increases the compound’s capability to attenuate the rate of soluble
aggregate growth via lateral binding. This statistical trend continues with gallic acid
acetylation of EGC to EGCG. TF, the phenolic derivative of EC and EGC, displays association
inhibition congruent with its precursor EGC. However, TFG, the phenolic derivative of EGC
and EGCG, shows a decreased attenuation of association, over TF. Overall, association
results indicate that EGCG is the superior inhibitor of soluble aggregate growth, displaying
the capability to attenuate both elongation and association.
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Previous research has suggested that polyphenols can bind to Aβ by two methods,
sequence specific binding or conformation dependent binding.17 Results from this aim
illustrate catechins’ capabilities to only effect Aβ soluble aggregate growth, suggesting
conformation dependent binding of Aβ. Conversely, theaflavins exhibit the ability to
affect every mechanistic step of Aβ aggregation, suggesting the compounds’ capabilities
to recognize several Aβ structures.
The resulting fibrillar product of Aβ aggregation is a summation of the different
mechanistic steps. Therefore, the inhibitory capabilities of the compounds at
oligomerization, elongation, and association steps can influence both the overall
aggregation propensity and aggregate morphology. Ability of catechins and theaflavins
to alter propensity of Aβ to aggregate is directly comparable to their ability to inhibit Aβ
oligomerization, with only the theaflavins able to significantly reduce the overall amount
of Aβ aggregates formed in their presences. Catechins have little effect on extent of
aggregation. However, they and their phenolic derivatives, theaflavins, have pronounced
effect on aggregate morphology. A robust analysis is formed by comparing the
morphological TEM images of fAβ produced.
fAβ made in the presence of EC is characterized by short well-defined lengths
compared to that of native fAβ. This observed morphology parallels with EC’s ability to
significantly reduce the rate of soluble aggregate elongation. The addition of a hydroxyl
group at the 3’ position from EC to EGC increases the capability of the compound to alter
fAβ morphology. fAβ made in the presence of EGC exhibits short well-defined lengths as
well limited lateral association compared to native fAβ. This morphological change is
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congruent with EGC’s increased ability to reduce association over EC. The acetylation of
EGC with gallic acid at position 3 to form EGCG results in further altered fAβ morphology.
EGCG produces fAβ with extremely short spindle-like structures with no lateral
association. The pronounced lack of length and thickness of the resulting fibrils can be
attributed to the mechanistic inhibitory capabilities of EGCG to attenuate soluble
aggregate growth. Fibrils are still produced in the presence of EGCG due to its inability to
inhibit Aβ oligomer formation. Though catechins are unable to reduce the amount of Aβ
aggregates formed in the overall Aβ1-40 monomer aggregation process, the TEM images
aligned with their mechanistic inhibitory capabilities reveals their ability to alter the
morphology of fAβ produce. Structure-toxicity relationship research has indicated a direct
correlation between fAβ morphology and toxicity18, this relationship could potential
explain the correlation of treatment with EGCG and reduced Aβ toxicity besides its
antioxidant capabilities.47,55,56
Catechins phenolic derivatives, theaflavins, in addition to reducing the propensity
of Aβ to aggregate alter fAβ morphology. TF has a reduced effect on fAβ morphology
compared to that of it catechin predecessors, as shown by the formation of fAβ with short
well-defined spindle-like lengths with equivalent native fAβ lateral association. Due to the
additive nature of the mechanistic steps of Aβ aggregation, the superior capability of TF
to reduce the elongation rate appears to negate its mechanistic inhibition of association.
Of the catechins and theaflavins, TFG has the most pronounced effect on the morphology
of fAβ made in its presence. When closely examined, the morphology of the Aβ produced
in the presence of TFG exhibits both reduced length and thickness, as well as altered
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morphology of the typically fAβ spindle like conformation. The Aβ conformation produced
by the presence of TFG more closely resembles an intermediate conformation between
oligomers and soluble aggregates based on the TEM classification by Fändrich 2006.49
While TFG’s capability to inhibit the late stages of Aβ aggregation is not as pronounced as
EGCG, Aβ morphological comparison shows TFG has a more pronounced effect on fAβ
formation. The difference in the mechanistic inhibitory capabilities of TFG compared to
EGCG is its ability to alter conformation and formation of Aβ oligomers. These results
place emphasis on alteration of Aβ at the earlier oligomeric formation.
Epidemiological28–30 and therapeutic research20,27,35,55,57–60 on catechins and more
recently theaflavins supports the growing recognition of their protective role against
neurodegeneration. Therapeutic research into the inhibitory capabilities of catechins has
focused on their ability to inhibit the earlier oligomerization process and the overall
aggregation of Aβ. Previous in vitro studies have shown the most promising therapeutic
catechin polyphenol to be EGCG,60,61 due to its ability to attenuate Aβ monomer
aggregation.55,62,63 From this aim and other papers64 it has been determined that the Aβ
aggregate detection method of ThT is not a viable monitoring technique for EGCG. Results
have shown that EGCG competes with ThT for binding of Aβ,64 resulting in discrepancies
between studies on the extent of EGCG capability to inhibit Aβ aggregation.60,63 What is
agreed upon is that EGCG does have an effect on Aβ aggregates produced in its
presence11,55,62–66 which has been correlated with reduce Aβ cytotoxicity.47,63,65,67 By
analyzing the mechanistic inhibitory capability of catechins and their phenolic derivatives,
theaflavins, it was revealed that the addition of the gallate group aids theaflavin inhibitory
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capability at oligomerization and overall aggregation, and the addition of a hydroxyl at
the 3’ position and a gallate group at the 3 position aids in catechins inhibitory capability
at association. Of the catechins, EGCG is the superior inhibitor, capable of attenuating Aβ
soluble aggregate growth. It was determined that while catechins are only able to
recognize Aβ soluble aggregate conformation they are still able to alter the resulting fAβ
morphology, potentially aiding in their ability to attenuate Aβ cytotoxicity. Theaflavins are
the only compounds able to significantly reduce the extent of Aβ aggregation, drawing a
direct correlation between compounds capability to reduce Aβ aggregate formation and
early modification of Aβ oligomerization.
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a

b

c

Figure 3.1. Petkova et al. model of Aβ secondary structure and potential fibrillar
interaction.48 (a) Depicts the secondary structure of a single cross β-sheet unit of Aβ,
residues 1-8 are structurally disordered and not shown, while residues 12-24 and 30-40
adopt β-strand conformations and form parallel β-sheets by hydrogen bonding. (b)
Depicts the proposed binding of Aβ through hydrogen bonding, forming fibrils that
contain two cross-β units with their hydrophobic faces juxtaposed. (c) Depicts the
proposed model of fAβ association, formed by juxtaposing the hydrophobic faces of two
cross-β units.
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Figure 3.1. Aβ1-40 monomer aggregation. Aβ1-40 monomer aggregation exhibits three
stages: the lag period, a rate limiting step where oligomerization occurs; the growth
phase, a period of soluble aggregate growth through elongation and association into fAβ;
and a plateau phase, where insoluble fAβ, soluble aggregates, and oligomers are in
equilibrium.
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Figure 3.3. Ability of catechins and theaflavins to inhibit Aβ1-42 oligomer formation.
Aβ1-42 is incubated alone (control, indicated by dashed line at one) or in the presence of
catechins, or theaflavins prior to dilution. Oligomerization is initiated via the dilution of
DMSO-solubilized A1-42 in 12 mM phosphate containing 1µM NaCl to final concentrations
of 15 µM Aβ1-42, 1% DMSO, 150 µM polyphenol. (a) A1-42 oligomer products resolved by
SDS-PAGE using a 4-20% Tris-glycine gel were transferred to nitrocellulose membrane and
probed with 6E10 antibody. (b)Volumetric analysis was performed for oligomer sizes of
100-250 kDa (solid bars) and 25-100 kDa (striped bars). Error bars represent SEM n=3-4.
*p<0.05, **p<0.01, ***p<0.001 for sample versus control.
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Figure 3.4. Altered conformation of Aβ1-42 oligomers confirmed by ANS. Aβ1-42
oligomers were prepared as in Figure 3.3 and were incubated alone (control, indicated by
dashed line at one) or in the presence of catechins (closed bars), or theaflavins (open
bars). Oligomers were diluted with ANS for a final concentration of 1 µM Aβ, 10 µM
polyphenol, and 100 µM ANS. ANS emission data is shown for the control (panel b), EGC
(panel c), and TFG (panel d). (a) Fluorescence was determined as the IAUC (450-550 nm)
(solid area) following blank subtraction (pattern area) and normalized to the control.
Parameters are expressed as mean + SEM, n=3. *p < 0.05 for sample versus control.
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Figure 3.5. Effect of catechins and theaflavins on soluble Aβ1-40 aggregate growth. 2 µM
Aβ1-40 soluble aggregates in 40 mM Tris-HCl (pH 8.0), was incubated alone (control, ), or in the
presence of 50 µM EC, EGC (), EGCG (), TF or TFG (). Elongation (panel a) and association
(panel b) were initiated by the addition of 30µM Aβ1-40 monomer and 150 mM NaCl, respectively.
Native soluble Aβ1-40 aggregate incubated alone and in the absence of monomer or NaCl served
as a negative control ( ). Samples were monitored by the DLS for Rh. The rate of soluble aggregate
growth was determined by linear regression. Results are expressed as fraction of control (control
indicated by the dashed line at 1); elongation (solid bars) and association (pattern bars) (panel c).
Error bars represent SEM, n=3-4. *p<0.05, ***p<0.001 sample versus control. +p<0.05, ++p<0.01,
and +++p<0.001 between samples.
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Figure 3.6. Comparison of different Aβ1-40 monomer aggregation monitoring techniques. (a)
For ThT analysis, fAβ1-40 was diluted to the equivalent of loading 15 µL Aβ monomer aggregation
assay (1:5 molar ratio of Aβ: polyphenol) into 140 µL 10 µM ThT, for a final concentration of 1.93
μM fAβ in 40 mM Tris-HCl (pH 8.0), 9.67 μM polyphenol or solvent (control), and 9.03 μM ThT
(solid bars). For LOC analysis fAβ1-40 were diluted to 10 μM in 40mM Tris-HCl (pH 8.0) in the
absence (control) or presence of 100 μM catechins or theaflavins. Each sample was dotted on 0.1
μM nitrocellulose paper right before and after the catechin or theaflavin was added. Each dot was
evaluated by densitometric analysis using LOC antibody detection (pattern bars). All samples were
quantified and reported as a fraction of the control (control indicated by the dashed line at one).
SEC-purified Aβ1-40 monomer was diluted to 20 μM in 40 mM Tris-HCl (pH 8.0) containing 150 mM
NaCl, the sample was then vortexed at 500 rpm. The amount of aggregation was monitored by
three techniques simultaneously. 1) ThT fluorescence using the area under the curve from 470500 nm (, panel b), this was accomplished by combining 140 µL of 10 µM ThT dye with 10 µL of
the sample. 2) LOC, large Aβ aggregate antibody, each dot was quantified by densitometric
analysis (, panel b). 3) DLS intensity (, panel b). All monitoring techniques are displayed as
fraction of control’s plateau (panel b). Error bars represent SEM, n=3. *p<0.05.
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Figure 3.7. Effect of catechins and theaflavins on Aβ1-40 monomer aggregation. SEC-purified
Aβ1-40 monomer was diluted to 20 μM in 40mM Tris-HCl (pH 8.0) containing 150 mM NaCl, samples
were vortexed at 500 rpm alone (control, ) or in the presence of 100 μM EC, EGC, EGCG ()
(panel a and b), TF (◊), or TFG () (panel c). Extent of aggregation, for the EC and EGC, was
evaluated via dot blot by LOC antibody detection. Each dot was quantified (panel a) and reported
as the fraction of control plateau (panel d). The extent of aggregation, for EGCG (panel b) and
theaflavins (panel c) were monitored via the intensity of DLS readings and graphed as fraction of
control plateau. Values were determined by averaging the plateau values of the control and
sequentially dividing all samples values by this average. All compounds’ inhibitory capabilities
were expressed as fraction of control (control indicated by dashed line at one) and evaluated for
plateau reduction (solid bars) and lag extension (pattern bars) (panel d). Error bars represent SEM,
n=3-4. **p<0.01, ***p<0.001 sample versus control; +p<0.05, THP grouped comparison; †p<0.05,
between samples.
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Figure 3.8. Morphology of Aβ1-40 aggregates formed in presence of catechins and theaflavins. Samples are composed of SEC-purified
Aβ1-40 monomer diluted to 20 μM in 40 mM Tris-HCl (pH 8.0) containing 150 mM NaCl, incubated under agitation alone (control, f) or
in the presence of 100 μM catechin or theaflavin, EC (a), EGC (b), EGCG (c), TF (d), and TFG (e). Extent of monomer aggregation was
evaluated by negative staining at a point in the equilibrium plateau. All samples were analyzed by TEM at 25 K magnification and are
shown relative to a scale bar of 200 nm.

CHAPTER 4: GREEN TEA CATECHINS AND BLACK TEA THEAFLAVINS ALTER KEY RNA
EXPRESSION IN ALZHEIMER’S DISEASE
4. 1

Introduction
The amyloid cascade hypothesis pinpoints the amyloidogenic cleavage of APP as

the initial step in the pathogenesis of AD. Because of the limited expression of APP within
the cell membrane, the amyloidogenic and non-amyloidogenic pathways compete for
substrate in the process of APP proteolysis.66,68 In the amyloidogenic pathway, APP is
cleaved sequentially by BACE1 and γ-secretase to produce sAPPβ and Aβ. Alternatively,
in the non-amyloidogenic pathway, APP is sequentially cleaved by α-secretase and γsecretase to produce sAPPα and α-CTF, or C83 (Figure 4.1). Intense focus has been given
to the investigation of APP proteolysis and Aβ amyloidogenic aggregation as possible
targets for AD therapy. This aim will investigate the capabilities of catechins and
theaflavins to alter the Aβ1-42 oligomer-induced expression of key RNAs in AD.
Aβ1-42 oligomers can act as cell stressors altering key RNA expression and upsetting
the precarious balance of APP proteolytic cleavage.42 Aβ1-42 oligomers cause the
upregulation of lncRNA antisense transcript for BACE1 (BACE1-AS), resulting in a rapid
feed forward mechanism of BACE1 upregulation.

42,41,69,70

BACE1-AS levels have been

shown to be elevated in individuals with AD. As an antisense transcript, BACE1-AS has a
complementary nucleotide sequence to BACE1 mRNA. When these complimentary
sequences bind, BACE1 mRNA is stabilized and its transcription promoted. BACE1, as the
47

rate limiting enzyme of APP cleavage,69 when increased shifts the balance of APP cleavage
towards the amyloidogenic pathway.71
A disintegrin and metalloproteinase (ADAM) family encompasses approximately
40 known ADAMs. Of those 40, 12 are catalytically active ADAMS that have the potential
to mediate the proteolytic cleavage of cell surface integral membrane proteins within
their juxtamembrane regions, releasing a soluble protein ectodomain into the
extracellular spaces.72 This process is commonly known as ectodomain shedding, making
the ADAMs involved often referred to as sheddases.72 ADAM9, ADAM10, and ADMAM17
are type 1 transmembrane glycoproteins responsible for ectodomain shedding and
possess α-secretase activity capable of proteolytic cleavage of APP.72–74 While ADAM9,
ADAM10, and ADAM 17 are putative α-secretases, the most prominent ADAM to exhibit
α-secretase activity is ADAM10.75,76 An alternative to the main strategy of therapeutic
research in AD, development of Aβ aggregation inhibitors, is the production of nonamyloidogenic pathway promoters, including upregulation of ADAM9, ADAM17, and
ADAM10.
As an alternative to reducing the amyloidogenic pathway or promoting the nonamyloidogenic pathway, Aβ production can be attenuated through reduction of APP or γsecretase. By reducing either or both of these proteins, resources for the production of
the amyloidogenic peptide Aβ are limited. γ-secretase is a multi-subunit membraneembedded protease complex, comprised of 4 integral membrane proteins: presenilin1
(PS1) or PS2, nicastrin, Aph-1 (anterior pharynx-defective 1), and Pen-2 (presenilin
enhancer 2).77 PS1 or PS2 acts as the catalytic subunit, while the other members allow for
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stabilization and maturation of the γ-secretase complex. Since the 1995 identification of
the involvement of PSEN1 and PSEN2 (PS1 and PS2 genes, respectively) mutations with
familial AD, the inhibition of γ-secretase has been investigated as a potential therapeutic
strategy.78–80 γ-secretase inhibitors also block the proteolytic cleavage of the Notch
receptor resulting in in vivo toxicity, thus undermining the inhibition of γ-secretase as a
reliable therapeutic.79 Alternatively, compounds that modulate versus inhibit γ-secretase
possess greater therapeutic potential for AD. As a key catalytic subunit, this aim focuses
on PS1 mRNA expression in relation to potential γ-secretase alterations.
The consumption of green tea and black tea is becoming widely regarded for its
diverse health benefits. Epidemiological28–30 and therapeutic research20,27,35,55,57–60 of
green tea and black tea components attribute the primary health benefits of the
beverages to their respective composition of monomeric catechin polyphenols and their
phenolic oligomers, theaflavins. Research from Chapter 3 divulged the ability of catechins
and theaflavins to inhibit Aβ aggregation, but that approach focuses upon only one of the
avenues in which they can interfere with the amyloidogenic pathway of AD. This aim
expands the knowledge of catechins and theaflavins as potential therapeutics by
investigating their ability to alter the processing of APP to release Aβ. In this aim, the
capability of catechins and theaflavins to alter Aβ1-42 oligomer-induced expression of key
AD-associated mRNAs was determined.
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4. 2

Materials and Methods

4. 2. 1 Materials
XTT was purchased from Sigma-Aldrich (St. Louis, MO). OxiSelectTM Oxygen
Radical Antioxidant Capacity (ORAC) activity assay was purchased from Cell BioLabs (San
Diego, CA). N-methyl dibenzopyrazine methyl sulfate (PMS) and E.Z.N.A. Total RNA
isolation kit I were purchased from VWR (Radnor, PA). Random Primers, MgCl2, dNTP, and
GoScript Reverse Transcriptase were purchased from Promega (Madison, WI). RNase
Inhibitor (human placenta) was purchased from New England BioLabs Inc. (Ipswich, MA).
PowerUp SYBR Green Mater Mix was obtained from ThermoFisher Scientific (Waltham,
MA). Ki67, APP, PS1, BACE1, ADAM9, ADAM10, and β-actin RNA primers were purchased
from Integrated DNA Technologies (Coralville, IA); sequences can be found in Table 4.1.
4. 2. 2 Evaluation of the Effect of Catechins and Theaflavins on Cell Viability
To ensure that catechins and theaflavins do not induce cytotoxicity, an XTT assay
was used to evaluate the effect of catechins and theaflavins on the viability of SH-SY5Y
human neuroblastoma cells. The XTT cell viability assay is a colorimetric assay that detects
cellular metabolic activity. In the assay, the yellow tetrazolium salt, XTT, is reduced to a
highly colored formazan dye by dehydrogenase enzymes in cells that are metabolically
active. This conversion only occurs in viable cells, creating an inverse correlation between
the amount of formazan produced and cellular toxicity. In a 96-well plate, cells were
seeded at 50,000 cells/well and allowed to settle and adhere (24 h) in a 1:1 mixture of
Ham’s F12K medium and DMEM. Medium was supplemented with 10% FBS, 100 units/mL
penicillin, and 100 μg/mL streptomycin. All cultures were maintained at 37°C in a humid
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atmosphere of 5% CO2 and 95% air. Seeded wells were then incubated in the absence
(negative control) or presence of 20 µM polyphenol or 0.2% Trition-X (positive control)
for 30 min. Wells were then treated with XTT in conjunction with PMS, an electron
coupling reagent that significantly improves the efficiency of XTT transport into cells, for
24 h. Metabolically active cells, viable cells, produce dehydrogenase enzyme reducing XTT
to highly colored formazan shifting the absorbance. The absorbance was analyzed at 450
nm. Results are expressed as fraction of control, and catechins and theaflavins were
classified as nontoxic if their levels of XTT reduction were not statistically lower than the
negative control.
4. 2. 3 Evaluation of Catechins’ Antioxidant Capacity
An oxygen radical antioxidant capacity (ORAC) activity assay was utilized to
evaluate the antioxidant capacity of catechins. The ORAC activity assay utilizes a
fluorescein probe that is oxidized by peroxyl radicals produced by free radical initiators.
As the probe is oxidized over time, the fluorescence is quenched. The presence of an
antioxidant compound prolongs the quenching of the fluorescence by blocking the
peroxyl radical oxidation until the antioxidant activity in the sample is depleted. 1 µM
catechin was combined with the 1 X fluorescein solution (30 min) followed by the addition
of the free radical initiator. The samples were then immediately evaluated for
fluorescence at an excitation and emission of 480 and 520 nm, respectively, for 90 min at
1 min intervals. This allowed the assay to be monitored to completion, or until depletion
of the fluorescence. The data was graphed as absorbance versus time, and the area under
the curve was determined and compared to the standard curve of Trolox, vitamin E analog
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(a known good antioxidant), to assess the ORAC value. Results are expressed as ORAC
value in comparison to Trolox ORAC value of one.
4. 2. 4 SH-SY5Y Cell Culturing for PCR experiments
Human neuroblastoma SH-SY5Y cells were seeded in a 6-well plate at 1,000,000
cells/well in 10% FBS and allowed to settle and adhere (24 h) in a 1:1 mixture of Ham’s
F12K medium and DMEM. Medium was supplemented with 10% FBS, 100 units/mL
penicillin, and 100 μg/mL streptomycin. All cultures were maintained at 37°C in a humid
atmosphere of 5% CO2 and 95% air. Cell treatments were diluted in 1 mL of 1% FBS, 10
units/mL penicillin, and 10 μg/mL streptomycin before being added to cells. Cell
treatments included untreated cells and cells treated with vehicle (containing DMSO and
H2O solvent substituted for Aβ and polyphenols, respectively) which served as negative
controls. SH-SY5Y cells were treated for 72 h; to prevent cell apoptosis via starvation, 1
mL of 1% FBS was added every 24 h after the initial PCR treatment.
4. 2. 5 PCR Treatment
Before the capabilities of catechins and theaflavins to alter the Aβ1-42 oligomerinduced expression of mRNAs were determined, the effect of excess catechins and
theaflavins alone was evaluated. Catechins and theaflavins were dissolved in filtered
dH2O to 3 mM before dilution to a final concentration of 10 µM polyphenol in 1% FBS
media for cell treatment.
The ability of catechins and theaflavins to alter the Aβ1-42 oligomer induced
expression of AD-associated mRNAs through antiaggregation, antioxidant, and synergistic
capabilities was analyzed via three treatments, respectively: oligomers were made in the
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presence of polyphenols, native oligomers were combined with excess polyphenol, and
oligomers were made in the presence of polyphenols combined with an excess of
polyphenols. All results were normalized to the vehicle treatment.
Catechins and theaflavins were evaluated for their capability to alter Aβ1-42
oligomer-induced expression of key AD-associated mRNAs through their ability to alter
oligomerization, including alterations of oligomer size distribution and conformation. Aβ142

oligomers, described in Section 2.6, were made in the absence (control) or presence of

a 1:10 molar ratio of catechins or theaflavins. Following oligomerization, oligomers were
immediately diluted to a final concentration of 0.1 µM Aβ1-42 and 0 M (control) or 1 µM
polyphenol in media containing 1% FBS.
The antioxidant capabilities of catechins and theaflavins to alter Aβ1-42 oligomerinduced expression of key AD-associated mRNAs were also evaluated. Aβ1-42 oligomers,
described in Section 2.6, were made in the absence of catechins or theaflavins. Following
oligomerization, Aβ1-42 oligomers were immediately diluted to a final concentration of 0.1
µM Aβ1-42 oligomers in 1% FBS media, containing 0 M (control) or 10 µM polyphenol.
Finally, catechins and theaflavins were evaluated for their ability to modify Aβ1-42
oligomer-induced expression of key AD-associated mRNAs through synergistic
capabilities, including both inhibition of oligomerization and antioxidant capabilities,
simultaneously. For this treatment, Aβ1-42 oligomers, described in Section 2.6, were made
in the presence of a 1:10 molar ratio of catechins or theaflavins. Following
oligomerization, Aβ1-42 oligomers were immediately diluted to a final concentration of 0.1
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µM Aβ1-42 oligomers and 0 M (control) or 1µM polyphenol in 1% FBS media, containing
0 M (control) or 10 µM polyphenol.
4. 2. 6 Isolation and Quantification of RNA
E.Z.N.A. RNA isolation kit I was utilized for total RNA isolation following 72 h
treatment. Treatment media was aspirated, and cells were immediately lysed with TRK
Lysis Buffer and scraped from their culture. Cell isolates were homogenized before being
precipitated with 70% EtOH via agitation (1200 rpm, 1.5 min). Total lysate was spun
through a HiBind RNA Mini column, trapping only the RNA within the filter. The RNA was
washed with 500 µL of RNA Wash Buffer I once, followed by two 500 µL washes with RNA
Wash Buffer II (twice) via column centrifugation. RNA was isolated from the column via
incubation (5 min) in DNase free H2O (70°C). Isolated RNA was diluted 1:50 in 10 mM TrisHCl (pH 8.0) containing 1 mM EDTA (TE buffer). Isolated RNA concentrations were
determined using absorbance at 260 nm, measured on a Life Science UV/Vis
Spectrophotometer DU 730 (Beckman Coulter, Brea, CA), and an extinction coefficient of
0.025 [(mg/ml)-1cm-1]. Purity of the sample was determined by the ratio of the nucleic
acid absorbance to the protein absorbance (A260/A280). Only samples having a ratio
between 1.8 and 2.1 were used for PCR. Isolated RNA was stored at -80°C for up to 1 year.
4. 2. 7 Determination of Relative RNA Expression via qRT -PCR
Reverse transcription was first initiated by the dilution of RNA to 1 µg and addition
of 1 µg of random primers in DNase free H2O for a total volume of 12 µL. RNA-random
primer mixture was heated for 5 min at 90°C before incubation (30 min) on ice. 4 µL of
Reverse Transcriptase buffer, 2 µL of MgCl2, 1 µL dNTP, 1 µL RNase Inhibitor, and 1 µL
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Reverse Transcriptase were added to the RNA-random primer mixture for final
concentrations of 47.62 µM RNA, 47.62 µM random primers, 2.38 mM MgCl2, 0.476 mM
dNTP, 40 U RNase inhibitor, and 1 U reverse transcriptase in reverse transcriptase buffer.
The reverse transcriptase mixture was then incubated (1 h) at 42°C before temperature
was increased to 92°C (10 min). cDNA produced was diluted 1:2 with DNase free H2O and
stored at -20°C until further use, up to 2 months.
Upon arrival, forward and reverse primers of Ki67, APP, PS1, ADAM9, ADAM10,
BACE1, and β-actin were diluted to 100 µM with TE buffer and stored at 4°C (Table 4.1).
qRT-PCR was performed in triplicate for each sample and primer, with a β-actin reference
sequence on each plate. The qRT-PCR contained a final concentration of 2 µM forward
primer, 2 µM reverse primer, and 25 ng cDNA in DNase free H2O and 5 µL PowerUp SYBR
Green Master Mix for a final volume of 10 µL. Samples were loaded into a DNase free 96
well plate and placed into the CFX96 Real-Time System and C1000 Thermal Cycler (BioRad, Hercules, CA). Using Bio-Ras CFX Manager 3.1 the instrument was programed to the
following parameters for all mRNAs: 95°C (4 min); 40 cycles of the sequence 95°C (30 sec),
56°C (30 sec), and 72°C (30 sec); 72°C (5 min); and a melting curve. A comparative
threshold cycle (Ct) was determined for each reference sequence. For each sample, the
reference sequence Ct values were normalized using Equation 4.1. Samples were then
normalized to the control using Equation 4.2. Relative mRNA expression levels are
reported as an n-fold difference of the sample to vehicle.
∆𝐶𝑡 = 𝐶𝑡𝑠𝑎𝑚𝑝𝑙𝑒 − 𝐶𝑡𝛽−𝑎𝑐𝑡𝑖𝑛

Equation 4.1

∆∆𝐶𝑡 = ∆𝐶𝑡𝑠𝑎𝑚𝑝𝑙𝑒 − ∆𝐶𝑡𝑣𝑒ℎ𝑖𝑐𝑙𝑒

Equation 4.2
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4. 3

Results

4. 3. 1. Catechins and Theaflavins do not Significantly Alter Cell Viability
The ability of catechins and theaflavins to alter cell viability was determined by
their ability to reduce XTT to a highly colored formazan dye by dehydrogenase enzymes,
found only in metabolically active cells. Treatment with catechins and theaflavins alone
resulted in formazan dye absorbance similar to the vehicle (Figure 4.2), indicated that the
presence of catechins and theaflavins do not alter the viability of cells.
4. 3. 2. Catechins Exhibit Antioxidant Capacity
Catechins antioxidant capacities were determined via an ORAC activity assay.
Antioxidant capabilities were evaluated as the polyphenol’s ability to delay decay of the
fluorescent probe by free radicals in relation to Trolox, a vitamin E analog. EGC and EGCG
exhibited capabilities similar to Trolox, and EC expressed significantly increased
antioxidant capacity compared to Trolox (Figure 4.3).
4. 3. 3. Catechins and Theaflavins have Negligible Effect on Key AD-associated mRNA
Expressions
To ensure accurate interpretation of catechins and theaflavins capability to alter
Aβ1-42 oligomer-induced expression of key AD-associated mRNAs, their effect on the
mRNAs in the absence of Aβ oligomers was determined. Utilizing the highest polyphenol
treatment concentration empolyed, the effect of 10 µM polyphenol treatment (72h) on
the RNA expression of Ki67, APP, PS1, ADAM9, ADAM10, and BACE1 was determined
(Figure 4.4). Results display no significant change in mRNA expression relative to the
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vehicle treatment, displaying that catechins and theaflavins alone have negligible effect
on the expression of key AD-associated mRNAs investigated.
4. 3. 4. Aβ1-42 Oligomers have Negligible Effect on Ki67 mRNA
Ki67 protein is a marker for cell proliferation,69 Ki67 mRNA was utilized to
determine if cellular treatments resulted in altered cell proliferation.41 Results represent
Ki67 mRNA expression for antiaggregation treatment (Figure 4.5a) and antioxidant
treatment (Figure 4.5b), as explained in Section 4.2.5. Ki67 mRNA expression was
unchanged by the presence of native or catechin and theaflavin modified Aβ1-42
oligomers, confirming that these treatments do not alter proliferation of SH-SY5y cells.
4. 3. 5. Catechins Alter Aβ1-42 Oligomer-induced Expression of APP mRNA
APP, a type 1 transmembrane protein, has the potential to undergo proteolytic
cleavage by BACE1 and γ-secretase to produces the amyloidogenic peptide Aβ. Aβ a
known cell stressor, at concentrations of 0.1 µM native Aβ1-42 oligomers resulted in the
upregulation of APP mRNA expression (Figure 4.6). Catechins and theaflavins were
investigated for their ability to attenuate this oligomer-induced upregulation of APP
mRNA. This upregulation was attenuated via EGCG antiaggregation (Figure 4.6a)
capability and EGC antioxidant (Figure 4.6b) capability. In fact, mRNA levels for these
treatments were maintained slightly below that of the vehicle.
4. 3. 6. Catechins and Theaflavins Fail to Downregulate PS1 mRNA Expression
mRNA of PS1, the catalytic activity subunit of the γ-secretase complex, was used
in reference to potential reduce γ-secretase activity, limiting the amyloidogenic cleavage
of APP. Native Aβ1-42 oligomers and modified oligomers formed in the presence of
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catechins and theaflavins did not significantly downregulate PS1 mRNA expression (Figure
4.7a). Alternatively, oligomers modified via TFG antioxidant capabilities resulted in the
upregulated of PS1 mRNA (Figure 4.7b).
4. 3. 7. Catechins Modified Aβ Oligomers to Upregulate ADAM10 mRNA, but not ADAM9
mRNA Expression
ADAM9 and ADAM10, sheddases with α-secretase activity, can cleave APP to
promote the non-amyloidogenic pathway. Thus, shift the balance away from the
amyloidogenic pathway. The presence of native Aβ1-42 oligomers did not result in altered
ADAM9 (Figure 4.8) or ADAM10 (Figure 4.9) mRNA expression. Additionally, modification
of oligomers by catechin and theaflavin antiaggregation (Figure 4.8a) and antioxidant
(Figure 4.8b) capabilities failed to alter expression of ADAM9 mRNA. Similarly, catechin
and theaflavin antioxidant (Figure 4.9b) capabilities failed to alter ADAM10 mRNA, but
through modulation of oligomerization (Figure 4.9a), EGC and EGCG upregulated
ADAM10 mRNA.
4. 3. 8. Catechins Attenuate Aβ1-42 Oligomer-induced Expression of BACE1 mRNA
Sequential cleavage of APP by BACE1 and γ-secretase results in the production of
the amyloidogenic peptide Aβ. Data has previously identified Aβ as cell stressor, capable
of upregulating BACE1 mRNA expression.

41,69

Results in this aim show congruent

capabilities with the presence of native Aβ1-42 oligomers resulting in the significant
upregulation of BACE1 mRNA (Figure 4.10). All catechins investigated were able to
attenuate the oligomer-induced upregulation of BACE1 mRNA through antiaggregation
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capabilities (Figure 4.10a), maintaining vehicle-like expression levels. In contrast,
theaflavin modified oligomers still expressed significant upregulation of BACE1 mRNA.
The antioxidant capacity of catechins and theaflavins to attenuate the oligomerinduced upregulation of BACE1 mRNA show, that only EC possesses the ability to
attenuate the BACE1 mRNA upregulation (Figure 4.10b), resulting in expression levels
similar to the vehicle. EGCG and TF displayed no antioxidant effect towards the reduction
of oligomer-induced upregulation of BACE1 mRNA, exhibiting significantly upregulated
BACE1 mRNA congruent to native oligomers.
Due to the individual antiaggregation and antioxidant capabilities of catechins and
theaflavins, a synergistic treatment was performed to assess their combined
antiaggregation and antioxidant potential. Synergistic results of EC express continued
attenuation of oligomer-induced upregulation of BACE1 mRNA (Figure 4.10c).
Additionally, the combined synergetic treatment of TF reduced the upregulation of
oligomer-induced BACE1 mRNA expression (p<0.05).
4. 4

Discussion
Epidemiological and research studies have associated catechins, abundantly

found in green tea, and theaflavins, abundantly found in black tea, with reduced incidence
of cognitive decline. This research sought to identify the manner in which catechins and
theaflavins act as potential therapeutics of AD. Focusing on the amyloid cascade
hypothesis, Chapter 3 identified the ability of catechins and theaflavins to mechanistically
attenuate Aβ aggregation, resulting in altered fAβ morphology. Current research has, and
continues to, identify the most toxic species of the Aβ aggregation pathway way as
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oligomers formed at the early stages of aggregation,15,81,82 placing emphasis on early
inhibition. Results from Chapter 3 identified theaflavins as the only compounds capable
of inhibiting oligomer formation and altering oligomer conformation. The inability of
catechins to alter Aβ oligomers does not appear to diminish their potential at AD
therapeutics. In vitro cell assays and in vivo models have shown a correlation between
catechins and attenuation of Aβ-induced cytotoxicity and cognitive impairment.3,17,38,40,65
Research has attributed catechins AD therapeutic potential to their ability antioxidant
capacity to scavenge ROS and act as metal-chelators.24,26,58,83,84 ORAC results concurred
with previous research that all catechins are good antioxidants. Additionally, research has
shown theaflavins as effective antioxidants, capabilities analogous to catechins.31,85–88Aβ
is a source of ROS, the peptide in the presence of metal ions such as iron and copper
generates free radicals via Fenton reaction.24 The resulting oxidative stress is able to
induce the upregulation of amyloidogenic cleavage of APP26,89,90 and potentiate its toxic
effect. An additional AD therapeutic strategy, to inhibition of Aβ aggregation, is the
alteration of the APP cleavage from the amyloidogenic pathway.
This research took a novel approach by analyzing the capability of catechins and
theaflavins to alter Aβ1-42 oligomer-induced expression of key AD-associated mRNAs
involved in APP processing to release Aβ. Catechins and theaflavins antiaggregation and
antioxidant capacity were assessed to alter oligomer-induced expression of key mRNAs in
three parts: 1) ability to reduce APP and PS1 mRNA, thus reducing the initial substrate
available for amyloidogenic cleavage, 2) ability to promote the non-amyloidogenic
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pathway by upregulating ADAM9 or ADAM10 mRNA, and 3) ability to attenuate the
amylogenic pathway by inhibiting BACE1 mRNA.
Aβ1-42 oligomers upregulated APP mRNA expression, congruent with previously
seen research.41 This shifted the initial focus of reducing APP mRNA expression to finding
a potential therapeutic to prevent this upregulation. Oligomer-induced upregulation of
APP mRNA is attenuated for oligomers made in the presence of EGCG and modified via
antioxidant capacity of EGC. These results align with the data that indicates the
neuroprotective action of EGCG may occur through more mechanisms than just
promotion of non-amyloidogenic APP cleavage.11
In response to the second component of this aim, catechins and theaflavins ability
to upregulate the expression of key non-amyloidogenic mRNAs were analyzed. It was
revealed that native and modified oligomers by catechins and theaflavins had no effect
on ADAM9. Additionally, ADAM10 mRNA expression was not altered by native oligomers.
However, oligomers made in the presence of EGC and EGCG resulted in significantly
upregulated ADAM10 mRNA. These results align with previous studies that show
incubation with EGCG promotes the non-amyloidogenic cleavage of APP to produce
sAPPα via α-secretase,47,56,57,83 specifically the putative α-secretase ADAM10.68,91 It is
important to note that the most prominent ADAM to exhibit α-secretase activity is
ADAM10.76 This indicates the potential to upregulate the non-amyloidogenic cleavage of
APP by α-secretase.
The third component of this aim was to investigate the capabilities of catechins
and theaflavins to inhibit the amyloidogenic cleavage of APP by attenuating BACE1 mRNA
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expression. Congruent with previously research, BACE1 mRNA expression is upregulated
by Aβ.42 Oligomers made in the presence of all catechins attenuated oligomer-induced
upregulation of BACE1 mRNA, while through antioxidant and synergistic capabilities EC
was able to attenuate of oligomer-induced upregulation of BACE1 mRNA. Through the
studied capabilities of catechin and theaflavins to alter oligomer-induced expression of
key AD-associated mRNAs, it was determined that theaflavins do not alter or interact with
oligomers in a manner that aids in the reduction of initial APP and γ-secretase substrates,
promote the non-amyloidogenic pathway, or attenuate the amyloidogenic pathway.
Aβ1-42 oligomer-induced upregulation of APP and BACE1 mRNA are congruent with
other research,41 indicate the ability of Aβ to increase the APP substrate that can undergo
proteolytic cleavage as well as a shift towards its amyloidogenic cleavage, supporting the
feed-forward mechanism of Aβ production.41,42,70,92 It is thought that Aβ may act as a
transcription factor within the regulatory regions of AD-associated genes.93

This

oligomer-induced expression of key AD-associated mRNAs identifies several points of
actions, as potential therapeutic must attenuate. EC displays antiaggregation,
antioxidant, and synergistic capabilities to attenuate oligomer-induced upregulation of
BACE1 mRNA. These results are congruent with mice models exhibiting EC capability to
only alter β-secretase cleavage of APP, though effective at 100 nM concentrations.38 EGC
and EGCG exhibit capabilities as antiaggregants and antioxidants to not only attenuate
the oligomer-induced upregulation of APP and BACE1 mRNA but also to modify oligomers
that result in the upregulation of ADAM10. These results illustrate the capability of
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catechins to maintain initial APP substrate levels while shifting the upregulation of the
amyloidogenic cleavage to the non-amyloidogenic cleavage.
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Table 4.1. Primer Sequences.
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6

65
6
Figure 4.1. Amyloidogenic and non-amyloidogenic cleavage of APP.43 In the amyloidogenic pathway BACE1 and γ-secretase
sequentially cleave APP to produce Aβ peptide that can then aggregate. Alternatively, in the non-amyloidogenic pathway α-secretase
and γ-secretase sequentially cleave APP.
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Figure 4.2. Cell viability after treatment with catechins and theaflavins. Human
neuroblastoma SH-SY5Y cells were incubated in the absence (control, indicated by dash
line at 1) or presence of 20 µM polyphenol or 0.2% Trition-X (negative control) for 30 min.
Cells were assessed for metabolic activity using XTT as described in Section 4.2.2.Error
bars indicate SEM n=3-4, **p<0.01, compared to control.
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Figure 4.3. Antioxidant capacity of catechins. 1 µM EC, EGC or EGCG was incubated with
1X fluorescein solution, for assessment of antioxidant capacity using an ORAC assay,
described in Section 4.2.3. Data is shown as ORAC value relative to Trolox (indicate4d by
dashed line at 1). Error bars represent SEM n=3-4, **p<0.01, compared to control.

67

Figure 4.4. Catechins and theaflavins alone have negligible effect on AD-associated
mRNAs. Human neuroblastoma SH-SY5Y cells were incubated in the absence (vehicle,
indicated by dashed line at 1) or presence of 10 µM polyphenol. RNA was isolated with
E.Z.N.A RNA Kit 1 followed by reverse transcription and qRT-PCR as detailed in Section
4.2.5. Expression relative to the vehicle (dashed line at one) was determined for Ki67
(panel a), APP (panel b), PS1 (panel c), ADAM9 (panel d), ADAM10 (panel e), and BACE1
(panel f). Error bars represent SEM, n=3-4.
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Figure 4.5. Cell treatments display negligible effect on Ki67 mRNA. SH-SY5Y cells were
treated for 72 h with a final concentration of 0.1 µM Aβ1-42 oligomers made in the absence or
presence of 10-fold molar excess polyphenol (panel a), or final concentrations of 0.1 µM native
Aβ oligomers and 10 µM polyphenol (panel b). RNA was isolated with E.Z.N.A RNA Kit 1
followed by reverse transcription and qRT-PCR as detailed in Section 4.2.5. Expression relative
to the vehicle (dashed line at one) was determined for Ki67 mRNA. Error bars represent SEM;

n=8 for treatment with Aβ alone and n=3-4 for treatment with polyphenols.
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Figure 4.6. Effect of catechins and theaflavins on Aβ1-42 oligomers-induced
upregulation of APP mRNA. SH-SY5Y cells were treated for 72 h with a final concentration
of 0.1 µM Aβ1-42 oligomers made in the absence or presence of 10-fold molar excess
polyphenol (panel a), or final concentrations of 0.1 µM native Aβ oligomers and 10 µM
polyphenol (panel b). RNA was isolated with E.Z.N.A RNA Kit 1 followed by reverse
transcription and qRT-PCR as detailed in Section 4.2.5. Expression relative to the vehicle
(dashed line at one) was determined for Ki67 mRNA. Error bars represent SEM; n=8 for
treatment with Aβ alone and n=3-4 for treatment with polyphenols and *p<0.05,
**p<0.01 for sample versus vehicle, and ++p<0.01 for samples versus native Aβ oligomers.
70

Figure 4.7. Effect of catechins and theaflavins on PS1 mRNA expression. SH-SY5Y cells
were treated for 72 h with a final concentration of 0.1 µM Aβ1-42 oligomers made in the
absence or presence of 10-fold molar excess polyphenol (panel a), or final concentrations
of 0.1 µM native Aβ oligomers and 10 µM polyphenol (panel b). RNA was isolated with
E.Z.N.A RNA Kit 1 followed by reverse transcription and qRT-PCR as detailed in Section
4.2.5. Expression relative to the vehicle (dashed line at one) was determined for Ki67
mRNA. Error bars represent SEM; n=8 for treatment with Aβ alone and n=3-4 for
treatment with polyphenols.
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Figure 4.8. Effect of catechins and theaflavins on ADAM9 mRNA expression. SH-SY5Y
cells were treated for 72 h with a final concentration of 0.1 µM Aβ1-42 oligomers made
in the absence or presence of 10-fold molar excess polyphenol (panel a), or final
concentrations of 0.1 µM native Aβ oligomers and 10 µM polyphenol (panel b). RNA was
isolated with E.Z.N.A RNA Kit 1 followed by reverse transcription and qRT-PCR as detailed
in Section 4.2.5. Expression relative to the vehicle (dashed line at one) was determined
for Ki67 mRNA. Error bars represent SEM; n=8 for treatment with Aβ alone and n=3-4 for
treatment with polyphenols
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Figure 4.9. Effect of catechins and theaflavins on ADAM10 mRNA expression. SH-SY5Y
cells were treated for 72 h with a final concentration of 0.1 µM Aβ1-42 oligomers made
in the absence or presence of 10-fold molar excess polyphenol (panel a), or final
concentrations of 0.1 µM native Aβ oligomers and 10 µM polyphenol (panel b). RNA was
isolated with E.Z.N.A RNA Kit 1 followed by reverse transcription and qRT-PCR as detailed
in Section 4.2.5. Expression relative to the vehicle (dashed line at one) was determined
for Ki67 mRNA. Error bars represent SEM; n=8 for treatment with Aβ alone and n=3-4 for
treatment with polyphenols and *p<0.05 modified oligomers versus native oligomers.
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Figure 4.10. Effect of catechins and theaflavins on Aβ1-42 oligomers-induced
upregulation of BACE1 mRNA. SH-SY5Y cells were treated for 72 h with a final
concentration of 0.1 µM Aβ1-42 oligomers made in the absence or presence of 10-fold
molar excess polyphenol (panel a), or final concentrations of 0.1 µM native Aβ oligomers
and 10 µM polyphenol (panel b), or final concentrations of 0.1 µM Aβ oligomers made in
the absence (Aβ control) or presence of 10-fold molar excess polyphenol and 10 µM
polyphenol (panel c). RNA was isolated with E.Z.N.A RNA Kit 1 followed by reverse
transcription and qRT-PCR as detailed in Section 4.2.5. Expression relative to the vehicle
(dashed line at one) was determined for Ki67 mRNA. Error bars represent SEM; n=8 for
treatment with Aβ alone and n=3-4 for treatment with polyphenols +p<0.05 and ++p<0.01
modified oligomers versus native oligomers.
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CHAPTER 5: CONCLUSIONS
AD currently affects an estimated 5.4 million Americans. This number is
anticipated to reach 13.8 million in 2050, placing prominence for a therapeutic. Current
AD therapeutic research investigates many facets of the disease, including but not limited
to amyloidogenic pre- and post-processing of Aβ, a key protein in AD pathogenesis.
Epidemiological studies have shown a direct correlation between green tea, rich in
catechin polyphenols, and black tea, rich in theaflavin polyphenols, consumption with
reduced incidence of cognitive decline.29,30 Based on these and other studies supporting
the natural cognitive health benefits of catechins and theaflavins, this study sought to
identify their potential as AD therapeutics targeting the amyloidogenic pre- and postprocessing of Aβ. In this study, catechins’ and theaflavins’ potential to act as multi-target
therapeutic drugs for AD was analyzed for their ability to 1) alter the mechanistic
aggregation of Aβ and 2) alter basal and Aβ1-42 oligomer-induced expression of key ADassociated mRNAs.
In Chapter 3, catechins and theaflavins’ capability to attenuate the mechanistic
aggregation of Aβ was determined. The polyphenols examined varied in their derivation
from the original parent compound EC. EC hydroxylates to EGC; EGC undergoes gallic acid
acetylation to form EGCG. Theaflavins are produced during fermentation by the oxidative
coupling of catechins. EC and EGC oxidatively couple to form TF, and EGC and EGCG
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oxidatively couple to form TFG. Mechanistic aggregation results show that catechins
displayed inhibitory capabilities only at the late stages, suggesting structural recognition
of only large aggregates, while theaflavins exhibit inhibitory capabilities at every
mechanistic step of the pathway, suggesting the capability to recognize multiple
aggregate confirmations.
The ability of catechins and theaflavins to alter the overall Aβ1-40 monomer
aggregation proved to be congruent with the summation of the inhibitory capabilities at
the individual mechanistic steps of Aβ aggregation, as shown by altered morphology of
fAβ made in their presence. Catechins were unable to inhibit the earlier oligomerization
process of Aβ aggregation, but were able to significantly reduce the rate of elongation
and association. Due to their inability to inhibit the early oligomerization, catechins were
unable to reduce the total Aβ aggregates formed, but because of the late stage inhibitory
capabilities, catechins were able to alter the morphology fAβ made in their presence.
Fibrils made in the presence of catechins displayed decreasing lateral association and
length from EC to EGC to EGCG, trending with structural derivation. Theaflavins exhibit
similar inhibitory capabilities as catechins towards soluble aggregate growth, but are
additionally able to reduce Aβ1-42 oligomer formation and the total amount of Aβ
aggregates formed in their presence. This result suggests that the amount of total Aβ
aggregates formed is more dependent upon the earlier nucleation phase of aggregate
growth. TFG, the phenolic derivative of EGC and EGCG, showed prominent attenuation of
both large (100-250 kDa) and small (25-100 kDa) oligomer species as well as moderate to
significant attenuation of the rate of elongation and association. The sum of its
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capabilities at every mechanistic step resulted in the most altered form of fAβ
morphology, which closely resembled an intermediate conformation between oligomers
and soluble aggregates.49
Chapter 3 analyzed catechins and theaflavins capabilities to attenuate the postprocessing aggregation of Aβ. To expand on their innate abilities to reduce cognitive
impairment, Chapter 4 examined their capabilities to alter the pre-processing of Aβ from
APP. Chapter 4 research took a novel approach by analyzing the capability of catechins
and theaflavins to alter Aβ1-42 oligomer-induced expression of key AD-associated mRNAs.
Catechins’ and theaflavins’ ability to alter the production of Aβ was analyzed in three
parts: 1) the ability to reduce APP and PS1 mRNA, 2) the ability to promote the nonamyloidogenic pathway by upregulating ADAM9 or ADAM10 mRNA, and 3) the ability to
attenuate the amylogenic pathway by inhibiting BACE1 mRNA. Results showed that
catechins, over theaflavins, displayed capabilities to alter Aβ-oligomer induced expression
of key AD-associated mRNAs. Congruent with previous observations, Aβ1-42 acts as cell
stressor resulting in the upregulation of APP and BACE1 mRNA.41 These results are not
only indicative of Aβ’s potential to increase the amyloidogenic cleavage of APP but its
potential to increase APP, producing more initial substrate to undergo proteolytic
cleavage. Results demonstrate that catechins possess the potential to prevent the
amyloidogenic cleavage of APP and promote non-amyloidogenic cleavage. All catechins
exhibits the capability to attenuate oligomer-induced upregulation of BACE1 through
antiaggregation capabilities and thus the potential to reduce the amyloidogenic cleavage
of APP. Aβ1-42 oligomers made in the presence of EGC and EGCG exhibit the capability to
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upregulate ADAM10 mRNA. Upregulation of ADAM10, the most prominent ADAM with
α-secretase activity, has the potential to promote the non-amyloidogenic cleavage of
APP.75,76 Additionally, EGC and EGCG are able to attenuate the Aβ1-42 oligomer-induced
upregulation of APP mRNA for oligomers made in its presence. This effect has the
potential to prevent upregulation of APP that can lead to more amyloidogenic cleavage.
In summary, this study demonstrated that catechins and theaflavins are able to
mechanistically inhibit aggregation of Aβ. It was found that the overall amount of Aβ
aggregates formed and the resulting fAβ morphology is dependent upon the mechanistic
step in which the compounds intervene. Only catechins were able to alter Aβ1-42 oligomerinduced expression of multiple AD-associated mRNAs, showing potential to attenuate the
amyloidogenic and promote non-amyloidogenic cleavage of APP. Combed, these studies
identify the capabilities of catechins to alter the pre-processing and post-processing of
Aβ, supporting their potential to act as multi-target therapeutics.
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CHAPTER 6: FUTURE PERSPECTIVES
Catechins and theaflavins exhibited the capability to alter fAβ morphology made
in their presence, presenting potential therapeutic benefits to attenuate Aβ-induced
toxicity, based on direct correlation between fAβ morphology and toxicity.18 Future
studies to analyze the ability of catechins and theaflavins to alter the toxicity of Aβ
aggregates formed in their presence will substantiate the potential of these compounds
as therapeutics.
Additionally, catechins were identified in Chapter 4 to alter expression of key ADassociated mRNAs. This action translates to the potential to alter expression of key
proteins involved in the amyloidogenic and non-amyloidogenic cleavage of APP. Future
studies will analyze protein expression of cell isolates from treatments congruent to
Section 4.2.4 PCR treatments, probing for BACE1, APP, and ADAM10 proteins. Results
congruent with PCR will provide stronger evidence that catechins, through
antiaggregation and antioxidant capabilities, are able to attenuate the feed-forward
mechanism of Aβ production by down regulating APP and BACE1 expression, while
upregulating ADAM10 expression. Resulting in attenuation of the amyloidogenic and
promotion of the non-amyloidogenic pathway.
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